The worldwide arm of the pivotal FALCON-HD programme for SKY-0515, an oral drug intended to lower both mutant huntingtin and PMS1, is recruiting people with Huntington's disease, according to its registration on ClinicalTrials.gov. The record, NCT07378644, is sponsored by Skyhawk Therapeutics, carries the study identifier SKY-0515-004-WW, gives an actual start date of January 6, 2026, and was last verified by the sponsor in June 2026. Skyhawk said on July 14, 2026 that the United States Food and Drug Administration had accepted an Investigational New Drug application and that regulators in Canada and the United Kingdom had cleared clinical trial applications, and that it plans to enrol up to 400 further participants with Stage 2 and early Stage 3 disease across more than 40 sites. The companion study in Australia and New Zealand, NCT06873334, is listed as active but no longer recruiting; the company reported on June 1, 2026 that it had closed with 144 participants, six months ahead of schedule.

The registry describes both studies as Phase 2/3, randomised, double blind, placebo controlled and dose ranging, with participants assigned to one of four arms: three once-daily oral dose levels of SKY-0515 or placebo. Blinded treatment runs for 12 months, after up to four weeks of screening and followed by four weeks of monitoring, with an independent data safety monitoring board. Eligibility is set at age 25 or older with genetically confirmed Huntington's disease and a CAG repeat length of at least 40. The primary outcome is change from baseline in the z-score of the Composite Unified Huntington's Disease Rating Scale, a measure combining functional capacity, motor score and two cognitive tests. For the worldwide study the registry gives an estimated primary completion of December 2028 and estimated completion of August 2029; the Australia and New Zealand study lists estimated primary completion in May 2027.

SKY-0515 is an investigational small molecule taken by mouth that acts on RNA splicing. The registry description states it is designed to lower huntingtin messenger RNA, reducing both normal and mutant huntingtin protein, and also to lower PMS1, a protein involved in somatic CAG repeat expansion. That dual target sets it apart from the antisense, gene therapy and RNA interference approaches tested in Huntington's disease so far. The data behind the pivotal programme are preliminary and were not placebo controlled at the point reported: in the first-in-human Phase 1/2 study the company reported a 69 per cent reduction in mutant huntingtin protein in blood at the 9 mg dose and reductions in PMS1 messenger RNA of up to 26 per cent at 12 months, alongside a mean change in the composite rating scale of plus 0.38 from baseline in pooled 4 mg and 9 mg groups, with 21 patients contributing data to month nine and 15 at month 12.

Those clinical comparisons were made against expected decline drawn from the Enroll-HD and TRACK-HD natural history datasets using propensity score weighting, not against a concurrent placebo group, and the company itself describes the pivotal programme as the test of whether the signal holds. There is no approved treatment shown to slow or halt Huntington's disease. Nothing in either registry record establishes that SKY-0515 slows progression; that is the question the two trials are designed to answer, and the earliest registered primary completion date is May 2027.